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Background: Chronic hepatitis (CH) in dogs is common and has the tendency to progress to liver
cirrhosis (LC). Circulating microRNAs might have the potential as markers for disease
progression.
Objectives: To investigate whether concentration of specific microRNAs in serum correlate with
the stage and grade of CH in Labrador Retrievers.
Animals: Twenty-two Labrador Retrievers with histological CH (n = 8), LC (n = 7), and normal
liver (NL, n = 7).
Methods: In this retrospective study, serum concentrations of miR-122, miR-29a, miR-133a,
miR-181b, and miR-17-5p were measured by quantitative real-time PCR and evaluated using
univariate linear regression in dogs. A multivariate model was fit including the grade of hepatitis
and the stage of fibrosis.
Results: Of the 5 microRNAs, only circulating miR-122 and miR-29a were significantly associated
with the grade of hepatitis and the stage of fibrosis. A positive correlation was identified between
the grade of hepatitis with miR-122 (rs = 0.79, P < .001) and miR-29a (rs = 0.78, P < .001). Both
miR-122 (rs = 0.81, P < .001) and miR-29a (rs = 0.67, P < .001) showed a significant positive corre-
lation with the stage of fibrosis. MiR-122 concentrations were significantly higher in the CH
(P < .01) and LC groups (P < .001) compared to the NL group. MiR-29a concentrations were signifi-
cantly higher in the CH (P < .001) and LC (P < .001) groups compared to the NL group.
Conclusions and Clinical Importance: Circulating miR-122 and miR-29a concentrations might
be useful for monitoring the response to treatment and progression of canine CH.
KEYWORDS
canine, cirrhosis, dog, fibrosis, liver injury
1 | INTRODUCTION
Chronic hepatitis (CH) is a common liver disease in dogs and is histo-
logically characterized by hepatocellular apoptosis or necrosis, a vari-
able mononuclear or mixed inflammatory cell infiltrate, and the
presence of fibrosis.1,2 Liver biopsy is the gold standard for diagnosing
chronic liver diseases, and necro-inflammatory activity (grade) and
amount of fibrosis (stage) can be scored histopathologically.3 Liver
fibrosis is defined as increased deposits of extracellular matrix (ECM)
proteins.4 Deposited ECM proteins include fibrillary collagens, nonfi-
brillary collagens, glycosaminoglycans, and proteoglycans.5 Liver cir-
rhosis (LC) is the result of an accumulation of ECM accompanied by
disruption of the hepatic architecture and the presence of
Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic hepa-
titis; ECM, extracellular matrix; HSCs, hepatic stellate cells; LC, liver cirrhosis;
NL, normal liver; TGF-β1, transforming growth factor β1.
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hyperplastic nodules.1 The presence of LC is a negative prognostic
factor of CH.6–8
Labrador Retrievers have increased risk for developing CH.2,8–11
This breed is predisposed to copper-associated hepatitis, and genetic
and dietary factors play a role in its pathogenesis.12 Copper toxicosis
in Labrador Retrievers was identified as a complex hereditary disease
affected by mutations in the genes coding for the copper transporters
ATP7B and ATP7A.13 In addition, dietary uptake of copper is associ-
ated with progression of CH,14,15 and D-penicillamine treatment is
effective in dogs with copper-associated hepatitis in this breed.10
Furthermore, idiopathic CH has higher incidence in Labrador
Retrievers.6,9,11
Alanine aminotransferase (ALT) is commonly considered to be the
most liver-specific enzyme.16 However, it has a low sensitivity for
detecting hepatitis in Labrador Retrievers.17 In addition, ALT activity
in advanced fibrosis might be within the reference range as a result of
a decrease in the number of hepatocytes.16 Histopathologic evalua-
tion is required not only to make a diagnosis but also to monitor pro-
gression during treatment. However, liver biopsies are an inherently
invasive method for dogs and carry some risk.18 Thus, the evaluation
of the applicability of minimal invasive biomarkers of disease severity
is an important effort in dogs with CH.
MicroRNAs are a family of noncoding RNAs that play an impor-
tant role in a variety of cell processes and are remarkably stable in
blood.19,20 Circulating microRNAs have been investigated in humans
as noninvasive biomarkers of liver inflammation, fibrosis, and
cancer.21–23 MiR-122 is the most abundant miRNA in the liver, and
the serum concentrations increase in humans with various liver inju-
ries.22,23 Recently, it is reported that circulating miR-122 has the
potential utility as a sensitive biomarker in early detection of liver
injury in Labrador Retrievers.24 In addition, a panel of circulating
microRNAs might be used to distinguish among parenchymal, biliary,
and neoplastic hepatobiliary diseases in dogs.25 In human, several
microRNAs have been reviewed as potential biomarkers for the diag-
nosis of liver fibrosis and disease progression.26 To our knowledge,
there is no report about the relationship of specific circulating micro-
RNAs and progression of fibrosis in canine CH.
The aim of our study was to investigate whether specific micro-
RNAs in serum correlate with the stage and grade of CH in Labrador
Retrievers. We hypothesized that circulating microRNAs would be dif-
ferent between healthy dogs and those with CH or LC.
2 | MATERIALS AND METHODS
2.1 | Animals
Our study included 15 client-owned Labrador Retrievers with histo-
logically CH and LC, referred to the Department of Clinical Sciences
of Companion Animals, Utrecht University, between 2010 and 2016
either because of liver-related clinical signs or increased liver enzyme
activities. In addition, clinically healthy dogs related to affected Labra-
dor Retrievers were recruited to participate in the ongoing research
program into copper-associated hepatitis of the Faculty of Veterinary
Medicine, Utrecht University.14 To confirm that these dogs were
clinical healthy or subclinically affected, liver biopsies and blood sam-
ples were collected according to the Act on Veterinary Practice, as
required under Dutch legislation. As a result, 7 client-owned Labrador
Retrievers without histological abnormalities in liver were included in
our study as normal liver (NL) group. Data concerning signalment and
laboratory and histopathology findings were retrospectively identified
from medical records. Samples were taken with informed consent of
the owners, and all procedures were known and approved by the Ani-
mal Welfare Body of the University of Utrecht.
2.2 | Blood samples
Blood samples were obtained from all dogs before the liver biopsy.
ALT and fasting bile acids (BA) concentrations were measured in hepa-
rinized plasma at the time of diagnostic workup at the Veterinary
Diagnostic Laboratory of Utrecht University (UVDL). Reference range
for ALT and fasting BA were established by UVDL and are <70 U/L
and <10 μmol/L, respectively. Serum samples were stored at −20C
or −70C until microRNA analysis.
2.3 | Histopathology
Liver biopsies were taken with a 14-G needle using a Tru-Cut device
under ultrasound guidance and processed as described previously.10
Samples were taken from the liver lobes that could be safely reached
under ultrasound guidance (in most cases, this was the left lateral liver
lobe). From 2 dogs, at 2 occasions, biopsies were available of which
the 2nd biopsy was obtained in a later stage of their disease. Based
on histological evaluation according to the World Small Animal Veteri-
nary Association standards,1 dogs were classified into 3 groups, NL,
CH, and LC, by a board-certified veterinary pathologist. Histopatho-
logical assessments were based on a published method.27,28 Grading
of hepatitis was defined on a scale of 0-5 for hepatic necro-
inflammatory activity grade: absent (0), slight (1), mild (2), moderate
(3), marked (4), and very marked (5), and staging of fibrosis using the
reticulin stain was defined on a scale of 0-4 for the degree of fibrosis:
absent (0), mild (1), moderate (2), marked (3), and very marked (4).3 A
semi-quantitative scoring of hepatic copper–stained rubeanic acid
was defined on a grading scale of 0-5.12,29
2.4 | RNA isolation
Total RNA was isolated from 50 μL of serum according to the manu-
facturer's protocol using a miRNeasy Serum/Plasma kit (Qiagen,
Hiden, Germany). After addition of QIAzol lysis reagent (250 μL) to
sera and incubation at room temperature for 10 minutes, 5.6 × 108
copies of synthetic Caenorhabditis elegans miR-39 (Qiagen) was added
as a spike-in control. Of note, 50 μL of chloroform was added and
incubated at room temperature for 2 minutes. After centrifugation at
12 000g for 15 minutes at 4C, the aqueous phase was transferred to
a fresh tube and 1.5 volumes of ethanol was added. RNA was purified
on an RNeasy minElute spin column (Qiagen), eluted in 14 μL RNase-
free water, and stored at −20C.
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2.5 | Quantitative real-time PCR
Mature microRNA was reverse transcribed using miScript II RT kit
(Qiagen) according to the manufacturer's instructions by polyadenylation
in combination with oligo-dT primers and 5× miScript HiSpec Buffer that
facilitates the selective conversion of mature microRNAs into cDNA. The
obtained cDNA was diluted to a total volume of 200 μL. Based on the
current human literature, the serum concentrations of miR-122, miR-29a,
miR-133a, miR-181b, and miR-17-5p were chosen to be measured in
dogs.26,30–34 Quantitative real-time PCR was performed using the miS-
cript SYBR Green PCR kit (Qiagen). All PCRs were carried out in duplicate
on a CFX-384 Real-Time PCR Detection System (BioRad, Veenendaal,
The Netherlands). Each reaction consisted of 5 μL 2× QuantiTect SYBR
Green PCR Master Mix, 1 μL 10× miScript Universal Primer, 1 μL 10×
miR-specific primer (Qiagen), and 1 μL of the previously diluted cDNA.
The total reaction volume of each PCR was adjusted to 10 μL by adding
2 μL RNase-free water. The concentrations of all microRNAs were quan-
tified using absolute quantification via a standard curve, with quantities
normalized to the synthetic C. elegansmiR-39 as spike-in control.35
2.6 | Statistical analysis
All data of dog characteristics were reported as median (range). The
overall difference among groups was determined using the nonpara-
metric Kruskal-Wallis test, followed by Dunn's multiple comparison.
Linear regression was performed to investigate the relationship
between the grade of hepatitis and the stage of fibrosis with micro-
RNA expression levels. A univariate analysis was performed with the
microRNA expression levels as dependent variable and the grade or
stage as independent variables. In addition, a multivariate analysis was
performed, including grade, stage, and copper scoring. Copper scoring
was added as a confounder in our study. The natural logarithm of the
different microRNAs was taken to ensure the validity of all models,
which was checked by studying the residuals on normality and con-
stant variance. Spearman rank-correlation coefficients were calculated
between microRNA expression levels and grade of hepatitis, stage of
fibrosis, and copper score. A Wilcoxon rank sum test was performed
to test the differences between microRNA expression levels and his-
tological subgroups. P <.05 was considered statistically significant.
Data were analyzed in GraphPad PRISM for Mac OS X version 5.0b
software (GraphPad Software Inc., La Jolla, California) and R version
3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).
3 | RESULTS
3.1 | Characteristics of Labrador Retrievers
Serum samples of 22 Labrador Retrievers were analyzed. Characteris-
tics of the NL group (n = 7), CH group (n = 8), and LC group (n = 7)
are shown in Table 1.
3.2 | Serum microRNAs are associated with liver
fibrosis in Labrador Retrievers
The analysis of circulating microRNAs associated with the grade of
hepatitis and the stage of fibrosis is provided in Table 2. Upon univari-
ate analysis, both miR-122 and miR-29a were significantly associated
with the grade of hepatitis and the stage of fibrosis (P < .001 for all
analyses). These microRNAs were also statistically significant upon
multivariate analysis. Neither of the microRNAs was significantly asso-
ciated to copper scoring upon multivariate analysis.
A positive correlation was identified between the grade of hepatitis
with miR-122 (rs = 0.79, P < .001; Figure 1A) and miR-29a (rs = 0.78,
P < .001; Figure 1B). Both miR-122 (rs = 0.81, P < .001; Figure 2A) and
miR-29a (rs = 0.67, P < .001; Figure 2B) showed a significant positive
correlation with the stage of fibrosis. On histological stage, circulating
miR-122 concentrations were significantly higher in the LC group than
in the NL (P < .001) and CH (P < .05) groups (Figure 3A) and were sig-
nificantly higher in the CH group than in the NL group (P < .01). Circu-
lating miR-29a concentrations were not detected in the NL group and
were highly expressed in the CH and LC groups (Figure 3B).
Circulating miR-122 and miR-29a concentrations in 2 Labrador
Retrievers with different disease stage are shown in Table 3. Circulating
miR-122 concentrations were increased in dog 1 upon progression form
NL to CH and were decreased in dog 2 (progression CH to LC) in parallel
with plasma ALT concentrations. Circulating miR-29a concentrations
were increased in both dogs with a worsened stage of fibrosis.
4 | DISCUSSION
Liver cirrhosis, the end stage of CH, carries a very poor prognosis in
dogs.5,7,8 Therefore, a liver biopsy is often recommended for early
diagnosis and treatment although this invasive technique carries some
risk.6,18 Therefore, efforts have been made to investigate the
TABLE 1 Dog characteristics
NL (n = 7) CH (n = 8) LC (n = 7) P-value
Sex 1M, 3MC, 3FS 1F, 7FS 6MC, 1FS
Age (y) 4.8 (1.6-8.1) 8.7 (5.2-11.4)* 9.2 (6.1-12.1)* .01
ALT (U/L) 44 (27-56) 416 (68-779)** 508 (78-712)** <.001
BA (μmol/L) 1 (1-2) 12 (1-95) 72 (40-161)*** <.001
Grade of hepatitis 0 (0-0) 2 (0-3)* 2 (1-3)** .001
Stage of fibrosis 0 (0-0) 2 (1-3) 4 (3-4)*** <.001
Copper scoring 0 (0-1) 2 (1-2.5)* 2 (0-4)* <.001
Data are expressed as median (range).
Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic hepatitis; F, female; FS, female spayed; LC, liver cirrhosis; NL, normal liver; M,
male; MC, male castrated.
*P < .05 compared with NL.; **P < .01 compared with NL.; ***P < .001 compared with NL.
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possibilities for using noninvasive biomarkers to monitor disease pro-
gression. Mature microRNAs are emerging as biomarkers for hepato-
biliary diseases in humans because they can be detected and
quantified in the blood.21–23 MicroRNAs can be used as diagnostic
markers for hepatocellular injury and hepatobiliary diseases in Labra-
dor Retrievers and other canine breeds.24,25 Because various
FIGURE 1 Scatter plot with Spearman correlation coefficient (rs) of circulating miR-122 (A) and miR-29a (B) concentrations with the grade of
hepatitis in Labrador Retrievers
FIGURE 2 Scatter plot with Spearman correlation coefficient (rs) of circulating miR-122 (A) and miR-29a (B) concentrations with the stage of
fibrosis in Labrador Retrievers
TABLE 2 Univariate and multivariate analysis of microRNA variables associated with the grade of hepatitis and the stage of fibrosis in Labrador
Retrievers
Variable
Univariate Multivariate
Estimate P-value Estimate P-value
Grade of hepatitis miR-122 1.460 <.001 0.870 .023
miR-29a 2.030 <.001 1.086 .006
miR-181b 0.190 .366 0.140 .665
miR-133a 0.240 .491 0.620 .250
miR-17-5p 0.200 .255 0.330 .195
Stage of fibrosis miR-122 1.110 <.001 0.600 .046
miR-29a 1.580 <.001 0.800 .009
miR-181b 0.180 .256 0.210 .374
miR-133a −0.080 .775 −0.385 .342
miR-17-5p −0.004 .977 −0.240 .222
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microRNAs also play essential roles in hepatic fibrogenesis such as
hepatic stellate cell (HSC) activation, HSC proliferation, and ECM
deposition, microRNAs may serve as markers of disease progres-
sion.26,36 Thus, we assessed in our study whether circulation micro-
RNAs can be used as biomarkers to monitor the grade and stage of
CH in Labrador Retrievers.
Circulating microRNAs have been reported as biomarkers of
liver injury in various forms of human liver diseases such as chronic
viral hepatitis, nonalcoholic fatty liver disease/nonalcoholic steato-
hepatitis, cholestasis, and hepatocellular carcinoma, and their con-
centrations have been correlated with the severity of the
disease.21–23,26 Because most microRNAs show a high level of simi-
larity in dogs and humans,37 there is a possibility that circulating
microRNAs in dogs can also be used as biomarkers for disease pro-
gression in CH. Thus, we selected 5 candidates of circulating micro-
RNAs as biomarkers for fibrosis progression including miR-122,
miR-29a, miR-133a, miR-181b, and miR-17-5p based on the current
available human literature.30–34 As a result, we observed that miR-
122 and miR-29a correlated with the grade of hepatitis and the
stage of fibrosis. The serum concentrations of miR-133a, miR-181b,
and miR-17-5p were increased in human patients with LC.31,33,34
However, these circulating microRNAs were not significantly associ-
ated with the grade and stage in our dogs. In a study on circulating
microRNAs as biomarkers of chronic heart diseases in Dachshunds,
Hulanicka et al concluded that the microRNA findings from dogs
were not directly reflected in human medicine.38 Thus, circulating
microRNA concentrations in Labrador Retrievers with CH might also
differ between species and disease type.
Mature miR-122 has been characterized as a hepatocyte-derived
microRNA, accounting for about 70% of all hepatic microRNAs.23
Serum miR-122 concentrations were increased in acute liver injury
and was an earlier marker of hepatocellular damage than serum ALT
activity in humans.22,23 Circulating miR-122 values were increased in
Beagle dogs with acute hepatocellular necrosis induced by hepato-
toxic compounds in the absence of increases in ALT.37,39 Our previous
reports demonstrated that circulating miR-122 is a highly sensitive
marker for the detection of hepatocellular injury in Labrador
Retrievers,24 and it is increased in dogs with acute and CH.25 In our
study, circulating miR-122 showed a positive correlation with the
stage of fibrosis and grade of hepatitis in Labrador Retrievers. This is
in agreement with findings in humans where increased serum concen-
trations of miR-122 correlated with fibrosis stage and inflammation
activity in patients with CH-C and nonalcoholic fatty liver disease.40
However, circulating miR-122 concentrations correlated negatively
with increasing stages of fibrosis in patients with CH-C.41 This sug-
gests that reduced concentrations of circulating miR-122 might be
caused by their downregulation caused by liver damage and the loss
of hepatocytes.41 Circulating miR-122 concentrations have been
reported to be increased and to correlate with histological liver stage
and inflammation grade in human patients with various chronic liver
diseases.40,42 Serum miR-122 concentrations in dogs were higher in
the LC group than the CH group on histological stage. However, in
humans with LC, lower miR-122 concentrations in serum might be an
indicator of hepatic functional capacity and a useful prognostic param-
eter.32 Circulating miR-122 showed a positive correlation with ALT
activity in liver injury and hepatic copper accumulation in Labrador
Retrievers and tended to be higher in CH compared to AH in
dogs.24,25 Plasma ALT activity in our study was high in dogs with the
LC group as well as the CH group. This suggests that the inflammatory
activity was maintained in dogs with LC and indicates that the release
FIGURE 3 Circulating miR-122 (A) and miR-29a (B) concentrations in Labrador Retrievers with normal liver (NL, n = 7), chronic hepatitis (CH, n = 8),
and liver cirrhosis (LC, n = 7). *P < .05, **P < .01, ***P < .001
TABLE 3 Circulating miR-122 and miR-29a concentrations in
2 Labrador Retrievers with different disease stage
Dog 1 Dog 2
NL CH CH LC
Grade of hepatitis 0 1 2 2
Stage of fibrosis 0 3 2 3
Copper scoring 1 1 2 2
ALT (U/L) 107 439 779 172
BA (μmol/L) 1 57 95 53
miR-122 (copies) 235 1776 2873 1187
miR-29a (copies) 1 197 510 644
Abbreviations: ALT, alanine aminotransferase; BA, bile acids; CH, chronic
hepatitis; LC, liver cirrhosis; NL, normal liver.
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of miR-122 from hepatocytes into the systemic circulation continues
in our dogs, even with severe stages of fibrosis.
Mature miR-29 family is 1 of the most extensively studied
microRNAs in the pathophysiology of human liver fibrosis.26 It not
only plays an essential role in HSC activation and regulators of
hepatic fibrosis but is also associated with the development of renal,
pulmonary, and cardiac fibrosis in humans.30,36 Transforming
growth factor β1 (TGF-β1) is a key mediator in inducing HSC activa-
tion and transformation to fibroblastic cells in dogs.4,5 Although
there are microRNAs that control the expression of TGF-β1, their
role in liver fibrosis is not well understood. Serum miR-29a concen-
trations were down-regulated in humans with liver fibrosis/cirrhosis
compared to a healthy control group.30 The molecular process that
leads to lower serum concentrations of miR-29a in humans with LC
is not clear.30 Interestingly, circulating miR-29a concentrations in
our dogs were significantly higher in the CH and LC groups com-
pared to the NL group. In addition, circulating miR-29a concentra-
tions were positively correlated with the grade of hepatitis and the
stage of fibrosis. Mature miR-29a molecules are produced in similar
amounts by hepatocytes and HSCs in the liver.26 Thus, miR-29a
might be released form hepatocytes in the same manner as miR-122
concentrations are released in both CH and LC groups. Because cir-
culating miR-29a concentrations are virtually lacking in histologically
NLs, we believe that it is a more unequivocal marker for the pres-
ence of inflammation and fibrosis.
Although there was a correlation between circulating miR-122
and miR-29a concentrations with the grade of hepatitis and the stage
of fibrosis in our study, their levels overlapped in each grade and
stage, respectively. In addition, we measured these microRNAs longi-
tudinally in 2 dogs with different disease phase. Circulating miR-122
concentrations in these 2 dogs fluctuated with ALT activity, reflecting
liver injury, as was shown in previous studies.24,25 In addition, circulat-
ing miR-29a concentrations were increased with a worsened stage of
fibrosis. MiR-122 and miR-29a might be useful to serially monitor for
disease progression or response to treatment in Labrador Retrievers
with CH.
Our study has some limitations. This study was a retrospective
study only conducted in Labrador Retrievers, and a small number of
dogs were included. Therefore, the possibility of type II error cannot
be excluded. Because there were age differences between the NL
group and the CH and LC groups, this might be a confounding factor.
Furthermore, longitudinal follow-up data were only available from
2 Labrador Retrievers. Because the stage of fibrosis only changed
from 2 to 3 in 1 dog, it might be caused by variation in liver tissue
samples. In addition, only 1 pathologist involved in our study, and the
size of liver specimens collected by 14-G needle, and the fact that not
all liver lobes were sampled might influence the assessment of the
grade of hepatitis and the stage of fibrosis because of a low represen-
tative value of the biopsy.
In conclusion, we report that circulating miR-122 and miR-29a
concentrations were related to the grade and stage in Labrador
Retrievers with CH. Based on these results, we believe that these cir-
culating microRNAs might be useful for monitoring the response to
treatment and progression of disease in dogs with CH. However, fur-
ther work, including a larger number of dogs, different breeds, and
follow-up data over time, is needed to determine if specific micro-
RNAs can be used as a biomarker for the diagnosis of liver fibrosis
and disease progression in dogs with CH.
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